RE:Question?deadpatient wrote: Was ate going to amalgamate the i.p on its own, or is that a demand from a stalking big pharma?My hunch is we get taken out much fast than the timlines you folks are throwing out
The current goal is to strike a deal with a US and Europe pharma in those respective markets. That's the emphasis. Similar to the Nuance deal, but on a bigger scale for the larger markets.
There has been a ratio of 80/20 put out, as a probability of a licensing deal and a buy out respectively.
There's no indication that there has been a request by an outside company to amalgamate. However Antibe is aware enough and concluded that this needs to be done in order to be prepared for any potential buy out now or in the future, or any unsolicited offer that may come in.
It should go without saying that they are aware that an outright buy out would likely require the inclusion of the IP, as this is essentially what the aquirer would primarily be interested in.
So the goal currently is to find a partner, but also be fully prepared to have the optionality of attracting a potential aquirer.